Insmed to Present at May 2026 Investor Conferences
Rhea-AI Summary
Insmed (NASDAQ: INSM) announced management presentations at two investor conferences in May 2026: BofA Securities 2026 Healthcare Conference in Las Vegas on May 12, 2026 at 1:40 p.m. PT, and the 2026 RBC Capital Markets Global Healthcare Conference in New York City on May 20, 2026 at 10:30 a.m. ET. Webcasts will be available via the company's investor relations website and archived for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – INSM
In the Apr 30 session, INSM gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings call scheduling | Neutral | -0.5% | Set date and time for Q1 2026 results and business update call. |
| Apr 07 | Clinical trial setback | Negative | -1.8% | Phase 2b CEDAR HS study failed endpoints and HS program discontinued. |
| Mar 23 | Positive clinical data | Positive | +5.9% | Phase 3b ENCORE ARIKAYCE trial met primary and key culture endpoints. |
| Mar 05 | Equity inducement grants | Neutral | -4.2% | New-hire RSUs and options granted under 2025 Inducement Plan. |
| Feb 19 | Earnings and guidance | Positive | +6.5% | Reported 2025 revenue and cash plus 2026 BRINSUPRI and ARIKAYCE guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news-driven moves generally aligned with the tone of each announcement, with positive clinical and earnings updates seeing gains and negative or neutral items seeing flat-to-down reactions.
Over the past few months, INSM has reported several material updates. A positive Phase 3b ENCORE readout on Mar 23, 2026 and strong 2025 financial results with 2026 guidance on Feb 19, 2026 both saw shares gain. By contrast, the Phase 2b CEDAR miss disclosed on Apr 7, 2026 and multiple insider-related filings coincided with modest declines. A prior notice of the May 7, 2026 Q1 call also saw a small dip. Today’s conference announcement fits this pattern of routine investor-relations communication amid a backdrop of substantive clinical and financial milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- BofA Securities 2026 Healthcare Conference in
Las Vegas on Tuesday, May 12, 2026, at 1:40 p.m. PT. - 2026 RBC Capital Markets Global Healthcare Conference in
New York City on Wednesday, May 20, 2026, at 10:30 a.m. ET.
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-may-2026-investor-conferences-302754966.html
SOURCE Insmed Incorporated